Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies
Executive Summary
FDA says Novartis’ assessment of the long-acting beta agonist’s REMS, which consisted only of a communication plan, shows the “plan, and therefore the REMS, has met its goal.”